Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05853965 | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma(BELI(E)VE) | recruiting | Phase 1 / Phase 2 | 45 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT02334865 | SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy | active not recruiting | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER |
| 1 |
| May 15, 2026 |
| clinicaltrials |
| NCT07082270 | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT02362035 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies(KEYNOTE145) | completed | Phase 1 / Phase 2 | 161 | Acerta Pharma BVINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04093596 | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)(UNIVERSAL) | completed | Phase 1 | 73 | Allogene TherapeuticsINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 24 | Yale UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05514990 | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | active not recruiting | Phase 1 / Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05828511 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment(LINKER-MM4) | recruiting | Phase 1 / Phase 2 | 149 | Regeneron PharmaceuticalsINDUSTRY | 3 | May 13, 2026 | clinicaltrials |
| NCT05981209 | Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | active not recruiting | Phase 1 | 12 | Abdullah KhanOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06698744 | UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | David WaldOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05060627 | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | active not recruiting | Phase 1 / Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07377435 | DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06799026 | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 5) | active not recruiting | Phase 1 / Phase 2 | 208 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 106 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 43 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT04960579 | P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma(MM) | active not recruiting | Phase 1 | 275 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05392946 | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | active not recruiting | Phase 1 / Phase 2 | 49 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06163898 | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 4 | CelgeneINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma(LINKER-MM1) | recruiting | Phase 1 / Phase 2 | 387 | Regeneron PharmaceuticalsINDUSTRY | 7 | Apr 20, 2026 | clinicaltrials |
| NCT07537049 | BR101 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06484777 | A Clinical Study of SHR-9539 in Patients With Multiple Myeloma | recruiting | Phase 1 | 138 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04557150 | A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) | completed | Phase 1 | 225 | Hoffmann-La RocheINDUSTRY | 9 | Apr 13, 2026 | clinicaltrials |
| NCT04667663 | CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.(CPD-DARA) | active not recruiting | Phase 1 | 16 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07032714 | Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma(MAGENTA) | recruiting | Phase 1 | 25 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03984097 | A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) | completed | Phase 1 | 50 | TakedaINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT01054196 | Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study | active not recruiting | Phase 1 / Phase 2 | 52 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06048250 | Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT01502085 | Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens(RZD) | completed | Phase 1 / Phase 2 | 25 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02681302 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence(CPIT001) | terminated | Phase 1 / Phase 2 | 46 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05411497 | Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 5 | Mayo ClinicOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06536413 | ATRA and Carfilzomib in Plasma Cell Myeloma Patients(ATRA) | recruiting | Phase 1 / Phase 2 | 42 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07510100 | Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(FUMANBA-04) | not yet recruiting | Phase 1 / Phase 2 | 17 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT01242267 | Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT(Thal/Mel/Vel) | completed | Phase 1 / Phase 2 | 29 | Hackensack Meridian HealthOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05862012 | Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | recruiting | Phase 1 | 200 | Ichnos Sciences SAINDUSTRY | 7 | Apr 1, 2026 | clinicaltrials |
| NCT06270888 | Hypofractionation (Radiation) Trial for Multiple Myeloma | recruiting | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06223516 | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 60 | AbbVieINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | active not recruiting | Phase 1 | 224 | C4 Therapeutics, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 466 | CelgeneINDUSTRY | 11 | Mar 20, 2026 | clinicaltrials |
| NCT03441958 | ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06153251 | A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 187 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT07477912 | Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma(MSTH-CAR001) | recruiting | Phase 1 / Phase 2 | 30 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Mar 17, 2026 | clinicaltrials |
| NCT01615029 | Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 45 | Janssen Research & Development, LLCINDUSTRY | 5 | Mar 16, 2026 | clinicaltrials |
| NCT02886065 | A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | active not recruiting | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06348108 | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 32 | Alfred Chung, MDOTHER | 1 | Mar 13, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 18, 2026source: clinicaltrials